ASX-Dividend-Report-Banner

China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally

October 02, 2023 06:00 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 China Review Studio and Chinese Red Cross Foundation Release
Image source: Kalkine Media

The documentary outlines China's contribution to vaccine science, research, and production since the COVID-19 pandemic and includes a call for science and infectious disease research to be borderless.

BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese Red Cross Foundation recently released a documentary on YouTube named Generation Vax. Directed by internationally renowned director Mitchell Farkas, the film focuses on the theme of China's Covid-19 vaccine by deeply diving into the safety, effectiveness, and publicity of China's vaccines.

The film tells a series of touching COVID-19 vaccine scientific research stories from three perspectives, namely, China's vaccine research, production, and science, and features interviews with numerous key personnel from world-leading institutions, including Zhong Nanshan, an academician with the Chinese Academy of Engineering; Ben Cowling, an epidemiologist of School of Public Health, University of Hong Kong, as well as production experts and scholars around the world related to Covid-19 vaccine research and development.

The key challenge that China's vaccines are facing is the focus on using tried and tested inactivated vaccine technology and overall concern from the public in domestic and overseas. A lot of other countries around the world has begun to use the activated vaccine and the film delves into various aspects of the global response to China's vaccine initiatives.

The film also reveals the story of how clinical phase III of China's vaccine has been conducted in Brazil. Back in May 2020, when vaccine research and development entered the third phase of clinical trials, it was discovered that China did not have access to large-scale Covid infection data, leading to a collaboration between Sinovac Biotechnology and Brazil's Butantan Institute to implement what was called the S-Project, to vaccinate all adults in the city of Serrana, a small town in Sao Paulo State, Brazil, with the Sinovac vaccine in order to study and test the effect of mass vaccination on controlling the spread of the virus.

In the film, the vaccine clinical trial that has been conducted by China Sinopharm Group in the United Arab Emirates has also been highlighted with over 44,000 volunteers from 125 countries vaccinated with the Sinopharm vaccine. Zhang Yuntao, Chief Scientific Officer of Sinopharm CNBG, commented that it was China's fastest and largest Phase III clinical study of COVID-19 at the time, which also marks a milestone in how China's vaccine has been applied for massive-scale protection.

The second half of the film documents China's calls for the world to work together to face down public safety incidents together.

The documentary will be translated and broadcast internationally in the coming weeks and months on multiple platforms, including Salve TV in Germany, ATV in Hungary, BFC in Italy, TVT in Brazil, Soweto in South Africa, RED MEDIA's TV stations, SPB in Russia, SEA in Indonesia, TODAY TV channel, and Genflix.

For more information about the Documentary, please visit https://youtu.be/XKc5nu-mUOI

 

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.